Myeloma mortality statistics

Deaths

Deaths from myeloma, 2016, UK

 

Proportion of all deaths

Percentage myeloma is of total cancer deaths, 2016, UK

 

Age

Peak rate of myeloma deaths, 2014-2016, UK

 

Trend over time

Change in myeloma mortality rates since the early 1970s, UK

Myeloma is the 17th most common cause of cancer death in the UK, accounting for 2% of all cancer deaths (2016).[1-3]

In males in the UK, myeloma is the 16th most common cause of cancer death (2% of all male cancer deaths). In females in the UK it is the 16th most common cause of cancer death (2% of all female cancer deaths).

54% of myeloma deaths in the UK are in males, and 46% are in females.

Myeloma mortality rates (European age-standardised (AS) rates Open a glossary item) are similar to the UK average in all the UK constituent countries.

Myeloma (C90), Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Population, UK, 2016

  England Scotland Wales Northern Ireland UK
Male Deaths 1413 122 87 51 1673
Crude Rate 5.2 4.6 5.7 5.6 5.2
AS Rate 6.4 5.7 6.1 7.6 6.4
AS Rate - 95% LCL 6.1 4.7 4.8 5.5 6.0
AS Rate - 95% UCL 6.7 6.7 7.4 9.6 6.7
Female Deaths 1193 109 67 37 1406
Crude Rate 4.3 3.9 4.2 3.9 4.2
AS Rate 4.2 3.8 3.8 4.3 4.1
AS Rate - 95% LCL 4.0 3.1 2.9 2.9 3.9
AS Rate - 95% UCL 4.4 4.5 4.7 5.6 4.4
Persons Deaths 2606 231 154 88 3079
Crude Rate 4.7 4.3 4.9 4.7 4.7
AS Rate 5.1 4.6 4.8 5.7 5.1
AS Rate - 95% LCL 4.9 4.0 4.1 4.5 4.9
AS Rate - 95% UCL 5.3 5.1 5.6 6.9 5.3

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, October 2017. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, December 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2016, ICD-10 C90.

Last reviewed:

Myeloma mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2014-2016, on average each year around 6 in 10 (61%) deaths were in people aged 75 and over.[1-3] This largely reflects higher incidence and lower survival for myeloma in older people.

Age-specific mortality rates rise steadily from around age 50-54 and more steeply from around age 65-69. The highest rates are in the 90+ age group for males and the 85 to 89 age group for females.

Mortality rates are significantly higher in males than females in a number of (mainly older) age groups. The gap is widest at age 40 to 44, when the age-specific mortality rate is 3.1 times higher in males than females.

Myeloma (C90), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Population, UK, 2014-2016

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, October 2017. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp
  3. Data were provided by the Northern Ireland Cancer Registry on request, December 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2014-2016, ICD-10 C90.

Last reviewed:

Myeloma European age-standardised (AS) Open a glossary item mortality rates for males and females combined increased by 60% in the UK between 1971-1973 and 2014-2016.[1-3] The increase was larger in males than in females.

For males, myeloma AS mortality rates in the UK increased by 71% between 1971-1973 and 2014-2016. For females, myeloma AS mortality rates in the UK increased by 47% between 1971-1973 and 2014-2016.

Over the last decade in the UK (between 2004-2006 and 2014-2016), myeloma AS mortality rates for males and females combined remained stable. In males AS mortality rates remained stable, and in females rates remained stable.

Myeloma (C90), European Age-Standardised Mortality Rates per 100,000 Population, UK, 1971-2016

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Myeloma mortality rates have varied between age groups in males and females combined in the UK since the early 1970s.[1-3] Rates in 25-49s have decreased by 41%, in 50-59s have decreased by 27%, in 60-69s have remained stable, in 70-79s have increased by 65%, and in 80+s have increased by 226%.

Myeloma (C90), European Age-Standardised Mortality Rates per 100,000 Population, By Age, UK, 1971-2016

References

  1. Data were provided by the Office for National Statistics on request, October 2017. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, December 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1971-2016, ICD-10 C90.

Last reviewed:

Myeloma mortality rates are projected to fall by 17% in the UK between 2014 and 2035, to 5 deaths per 100,000 people by 2035.[1] This includes a smaller decrease for males than for females.

For males, myeloma European age-standardised (AS) Open a glossary item mortality rates in the UK are projected to fall by 16% between 2014 and 2035, to 6 deaths per 100,000 by 2035.[1] For females, rates are projected to fall by 22% between 2014 and 2035, to 4 deaths per 100,000 by 2035.[1]

Myeloma (C90), Observed and Projected Age-Standardised Mortality Rates, by Sex, UK, 1979-2035

 

It is projected that 3,835 deaths from myeloma (2,265 in males, 1,570 in females) will occur in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C90

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is no evidence for an association between myeloma mortality and deprivation for either males or females in England.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are similar for both males and females living in the most deprived areas compared with the least deprived.[1]

Myeloma (C90), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in myeloma mortality between people living in the most and least deprived areas in England has not changed in the period 2002-2011.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: UK, 2007-2011, ICD-10 C90

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Myeloma (C88 & C90) is the 16th most common cause of cancer death in Europe, with around 24,300 deaths from myeloma in 2012 (1% of the total). In Europe (2012), the highest World age-standardised Open a glossary item mortality rates are in Norway for both men and women; the lowest rates are in Albania for both men and women. UK myeloma mortality rates are estimated to be the 7th highest in males in Europe, and 10th highest in females.[1] These data are broadly in line with Europe-specific data available elsewhere.[2]

Myeloma (C88 & C90) is the 20th most common cause of cancer death worldwide, with around 80,000 deaths from myeloma in 2012 (1% of the total). Myeloma mortality rates are highest in North America and lowest in Western Africa, but this partly reflects varying data quality worldwide.[1]

References

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed December 2013.
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer (2013) 49, 1374-1403.

About this data

Data is for: Europe and worldwide, 2012, ICD-10 C88 & C90

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 2 out of 5 based on 15 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page